

LA JOLLA PHARMACEUTICAL CO  
Form 8-K  
June 01, 2011

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 27, 2011

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

Delaware

0-24274

33-0361285

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

4365 Executive Drive, Suite 300, San Diego,  
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(858) 452-6600

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Top of the Form

**Item 8.01**

**Other Events.**

On May 31, 2011, La Jolla Pharmaceutical Company (the Company ) reported that on May 27, 2011 it had converted approximately 14 shares of Series C-1<sup>1</sup> Convertible Preferred Stock and on May 31, 2011 it had converted approximately 5 shares of Series C-1<sup>1</sup> Convertible Preferred Stock into a combined total of 3,241,666 shares of common stock. Following these conversions, the Company had a total of 20,356,323 shares of common stock issued and outstanding as of May 31, 2011.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

*May 31, 2011*

By: */s/ Deirdre Y. Gillespie*

---

*Name: Deirdre Y. Gillespie  
Title: Chief Executive Officer*